ArticleRespirology case reports2025
Early Pseudoprogression After Tarlatamab in Small-Cell Lung Cancer: A Case Report.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Early Pseudoprogression Mimicking Pneumonitis After Tarlatamab Therapy: A Case Suggestive of Immune Cell-Associated Respiratory Syndrome (ICARS).Respirology case reports · 2025Article
- Continuing immune checkpoint inhibitors after pseudoprogression improves survival in lung cancer patients: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Early Pseudoprogression After Tarlatamab in Small-Cell Lung Cancer: A Case Report.Respirology case reports · 2025Article
- Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudoprogression, a transient radiographic flare caused by immune infiltration, is common after immune-checkpoint inhibitors but has not been reported with tarlatamab, a bispecific T-cell engager approved for third-line small-cell lung cancer (SCLC). A 57-year-old woman with extensive-stage SCLC and syndrome of inappropriate antidiuretic hormone secretion (SIADH) received tarlatamab. Within hours, she developed bone pain; Day 7 imaging showed marked tumour swelling and pleural effusion despite negative cytology and rising serum sodium. Therapy continued. By Day 13, computed tomography demonstrated regression of thoracic and hepatic lesions and falling pro-gastrin-releasing peptide (pro-GRP). Early pseudoprogression and paraneoplastic biomarker improvement may predict efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.